Exhibit 99.4
FOR IMMEDIATE RELEASE
| | | | | | |
| Contact: | | | | Adam C. Derbyshire | | Mike Freeman |
| | | | Senior Vice President and | | Executive Director, Investor Relations and |
| | | | Chief Financial Officer | | Corporate Communications |
| | | | 919-862-1000 | | 919-862-1000 |
SALIX PHARMACEUTICALS ANNOUNCES
3Q2006 FINANCIAL RESULTS
CONFERENCE CALL AND WEBCAST
RALEIGH, NC, October 24, 2006 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report third quarter ended September 30, 2006 financial results before the market opens on Tuesday, November 7, 2006.
The Company will host a conference call at 9:00 a.m. ET, on Tuesday, November 7, 2006. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at http://www.salix.com. A replay of the web cast will be available at the same location.
The telephone numbers to access the conference call are (800) 967-7184 (U.S. and Canada) or (719) 457-2633 (international.) The access code for the call is 6635554. A replay of the call will be available from 12:00 noon ET. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international.) The access code for the replay is 6635554.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix also markets
XIFAXAN®, VISICOL®, OSMOPREP™, AZASAN®, ANUSOL-HC® and PROCTOCORT®. In August 2006, the FDA approved MOVIPREP® for bowel cleansing prior to colonoscopy, and we intend to launch the product in mid-fourth quarter 2006. Balsalazide tablets, Granulated Mesalamine, SANVAR® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.
Salix trades on the NASDAQ Market under the ticker symbol “SLXP.”
For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.
